CONFEREES URGE BROAD FDA INTERPRETATION OF S 830'S EXPANDED ACCESS PROVISIONS
This article was originally published in The Gray Sheet
Executive Summary
FDA is instructed to adopt a broad definition of the expanded access to unapproved therapies provision included in the FDA Modernization Act (S 830) signed into law Nov. 21.